Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
San Francisco
California
94080
United States
Website: http://www.fiveprime.com/
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to improve the lives of patients with serious diseases. We have an industry-leading and differentiated drug discovery platform. Our comprehensive proprietary libraries of the extracellular proteome, differentiated screening capabilities and protein therapeutic generation and engineering capabilities comprise a unique and powerful IND engine that positions us to discover novel pathways and targets in immuno-oncology and will continue to generate important development programs. Our success with our drug discovery platform has led to a pipeline that is on track to more than double to five development programs in clinical trials across multiple indications in 2018. We also have several undisclosed research programs at different points of the target validation and molecule generation phases that have the potential to yield our next wave of development-stage therapeutic biologics. And we continue to fuel this process at the earliest stages with new screens planned this year.
Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
The company is in a strong financial position and has an effective executive team and Board of Directors. Discover more about Five Prime at www.fiveprime.com
Stock Symbol: FPRX
Stock Exchange: Nasdaq
246 articles about Five Prime Therapeutics, Inc.
-
Five Prime To Host Conference Call On Worldwide License And Collaboration Agreement With Bristol-Myers Squibb For CSF1R Antibody Program
10/15/2015
-
Five Prime Announces The Presentation Of Preliminary FPA008 Phase 1 Trial Data In Rheumatoid Arthritis Patients At The 2015 American College of Rheumatology Annual Meeting
10/7/2015
-
Open Monoclonal Technology, Inc. Announces OmniAb Alliance With Five Prime
10/6/2015
-
Five Prime To Present At The Leerink Partners Inaugural Immuno-Oncology Roundtable
9/28/2015
-
Five Prime' Phase Ia/Ib Trial Of FPA008 And OPDIVO (Nivolumab) Featured As A Trial-In-Progress At The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
9/21/2015
-
Five Prime Announces Initial Data From Ongoing Phase Ib Trial Of FP-1039 In Squamous Non Small Cell Lung Cancer And Mesothelioma
9/10/2015
-
Five Prime Initiates Patient Dosing In Phase Ia/IIb Trial Evaluating The Immunotherapy Combination Of FPA008 And OPDIVO (Nivolumab) In Six Tumor Types
9/9/2015
-
Five Prime Announces Oral Presentation Of Initial Data From Ongoing Phase Ib Trial Of FP-1039/GSK3052230 In Squamous Non Small Cell Lung Cancer And Mesothelioma At World Conference On Lung Cancer
8/24/2015
-
Five Prime Reports Second Quarter 2015 Results And Provides Business Update
8/7/2015
-
Five Prime To Announce Second Quarter 2015 Financial Results And Host Conference Call On August 6
8/3/2015
-
Five Prime and Inhibrx Ink $452.5 Million Cancer Deal Focusing on GITR Antibodies
7/17/2015
-
Five Prime Initiates Patient Dosing In Phase I/II Clinical Trial Evaluating FPA008 In Pigmented Villonodular Synovitis
7/13/2015
-
Five Prime To Present At The Jefferies and Co. Healthcare Conference
5/29/2015
-
bluebird bio Pads CAR T Arsenal With $131.5 Million Five Prime Pact
5/28/2015
-
Five Prime Therapeutics, Inc. Announces First Quarter 2015 Financial Results
5/14/2015
-
Five Prime Therapeutics, Inc. To Announce First Quarter 2015 Financial Results And Host Conference Call On May 13
5/8/2015
-
Five Prime Therapeutics, Inc. To Present At The Credit Suisse Antibody Day
5/4/2015
-
Five Prime Therapeutics, Inc. To Host Research & Development Day On May 5, 2015
4/23/2015
-
Vaccinex, Inc. Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics, Inc.
3/20/2015
-
Five Prime Therapeutics, Inc. Announces Fourth Quarter And Full Year 2014 Financial Result
3/18/2015